Helicobacter pylori eradication following first-line treatment failure in Europe: What, how and when chose among different standard regimens? A systematic review
Authors:
- 19 March 2021
- journal article
- review article
- Published by Wolters Kluwer Health in European Journal of Gastroenterology & Hepatology
- Vol. 33 (1S) , e66-e70
Abstract
Cure rate following standard first-line regimens for Helicobacter pylori eradication is decreasing so several patients require two or more treatments. Antibiotic susceptibility-based therapy, advised in current guidelines, is largely impracticable in clinical practice. Some ‘standard’ regimens (triple therapies based on either levofloxacin or rifabutin, bismuth-based quadruple therapies, sequential, concomitant and hybrid therapies) were empirically used as rescue therapies. We performed a systematic review on recent studies carried out in European countries dealing with these regimens. A total of 24 studies, with 3804 patients, were identified. As second-line therapy, Pylera (89.2%) and sequential therapy (92.5%) achieved significantly higher cure rates as compared to all the other regimens. As third-line therapy, levofloxacin-based therapy (84.1%) and Pylera (83.6%) achieved similarly high cure rates, whereas standard, bismuth-based quadruple therapy (64.1%) achieved the lowest. As a rescue therapy, the success rate was close to 75% following all therapies used, with data on rifabutin-based regimen consolidated in the larger sample size. Overall, levofloxacin–amoxicillin triple therapy achieved higher eradication rates when the 14- rather than 10-day regimen was used (87.1 vs. 72.2%; P = 0.003). Among bismuth-based therapies, Pylera achieved a significantly higher eradication rate than standard quadruple therapy (88 vs. 67%; P < 0.0001). These data suggest that a wise ‘therapeutic package’ following first-line therapy could be Pylera, levofloxacin- and rifabutin-based therapy, as long as Pylera therapy was not used as a first-line regimen and levofloxacin-based regimen was administered for 14 days.Keywords
This publication has 36 references indexed in Scilit:
- Systematic review: third-line susceptibility-guided treatment for Helicobacter pylori infectionTherapeutic Advances in Gastroenterology, 2016
- Rifabutin Containing Triple Therapy and Rifabutin with Bismuth Containing Quadruple Therapy for Third‐Line Treatment of Helicobacter pylori Infection: Two Pilot StudiesHelicobacter, 2016
- Guidelines for the management of Helicobacter pylori infection in Italy: The III Working Group Consensus Report 2015Digestive and Liver Disease, 2015
- Beyond Maastricht IV: are standard empiric triple therapies for Helicobacter pylori still useful in a South-European country?BMC Gastroenterology, 2015
- Quadruple Rescue erapy aer First and Second Line Failure for Helicobacter pylori Treatment: Comparison between Two Tetracycline-Based RegimensJournal of Gastrointestinal and Liver Diseases, 2014
- Helicobacter Pylori First-Line and Rescue Treatments in the Presence of Penicillin AllergyDigestive Diseases and Sciences, 2014
- Use of a combination formulation of bismuth, metronidazole and tetracycline with omeprazole as a rescue therapy for eradication of Helicobacter pyloriAlimentary Pharmacology & Therapeutics, 2014
- Third-Line Rescue Therapy with Bismuth-Containing Quadruple Regimen After Failure of Two Treatments (with Clarithromycin and Levofloxacin) for H. pylori InfectionDigestive Diseases and Sciences, 2013
- Predicting Helicobacter pylori EradicationJournal of Clinical Gastroenterology, 2012
- A clinical practice viewpoint: to culture or not to culture Helicobacter pylori?Digestive and Liver Disease, 2003